Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
February 23, 2023
Earnings Call Speaker Segments
Jessi Rennekamp
executiveThanks, operator. Good morning, everyone, and welcome to Agios’ fourth quarter and year-end 2022 conference call. To view the slides for today’s call, go to the Investors part of our website, agios.com. Joining me today with prepared remarks are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Before we begin, I’d like to remind everyone that portions of this call will involve forward-looking statements. Due to a range of risks, uncertainties and other factors, including those described in our most recent SEC filings and any future SEC filings we may make, actual events and results could differ materially from those expressed or implied by any forward-looking statements. With that, I’ll hand the call over to Brian.
Brian Goff
executiveHello, everyone, and thanks for being here this morning. Agios stands as the trailblazing pioneer in PK activation, committed to creating and providing groundbreaking treatments for individuals suffering from uncommon illnesses. Thanks to the united efforts of the Agios workforce, we achieved remarkable strides during the last 12 months in pursuit of our objective to establish a PK activation portfolio centered on blood-related conditions that possess a shared fundamental disease mechanism, few therapeutic choices, and a severe unmet medical need. Specifically, I want to acknowledge the outstanding execution shown by our research and development group in advancing PYRUKYND, our first-in-class PK activator, as the initial and sole approved disease-modifying treatment for grown-ups affected by PK deficiency. PYRUKYND received approval across the United States, European Union, and Great Britain during 2022 and stands as the foundation of our expanding PK activation portfolio, which holds the prospect of 2 more indications by 2026. Alongside these authorizations, we achieved notable headway throughout our wider clinical-stage pipeline, such as our 5 active pivotal trials, and fulfilled the bold clinical development objectives we set forth at the start of the prior year. In particular, we keep producing steady and persuasive results with our PK activators spanning various disease categories, underscoring how this distinct mechanism of action could revolutionize patient function, quality of life, and long-term outcomes not just in PK deficiency, but additionally in thalassemia, sickle cell disease, and lower risk MDS. During 2022, findings from our clinical portfolio were shared at key medical conferences, such as the yearly gatherings of the European Hematology Association and the American Society of Hematology, and appeared in leading medical publications like The Lancet and the New England Journal of Medicine. After the third complete quarter since launching PYRUKYND for PK deficiency, we remain heartened by the favorable response from patients, doctors, and payers, along with the difference PYRUKYND is making for a population that formerly lacked any therapeutic alternatives. As we have previously stated, we still hold the view that this rollout will be gradual and consistent and will serve as a capability-building foundation to enable possible growth into considerably bigger patient groups. Even so, we aim to enhance the launch momentum and capture the complete potential of the opportunity before us. Toward that goal, in December of the prior year, we named Tsveta Milanova as Chief Commercial Officer. Tsveta is an experienced commercial figure who contributes extensive knowledge in introducing and commercializing medications for rare diseases and hematology, with a specific emphasis on worldwide market access and operations. Her background and guidance will be essential as we keep fortifying our commercial strengths to both optimize the promise of the present launch in PK deficiency and get ready for possible upcoming launches in thalassemia and sickle cell disease within the coming years. We concluded 2022 with an admirable cash situation, holding roughly $1.1 billion on the balance sheet. That takes into account the single, non-recurring amount we got during 2022's fourth quarter, after we sold our royalty rights tied to U.S. net sales of TIBSOVO to Sagard. Our cash should carry us through finishing the programs already underway, and it should also let us grow the portfolio past PK activation by way of disciplined business development, plus move our earlier-stage pipeline forward. On all of these goals, we look for meaningful strides during 2023. To be specific, around the midpoint of this year, we should finish bringing patients into the Phase 3 ENERGIZE and ENERGIZE-T trials of PYRUKYND in thalassemia, and report the data readout from the Phase 2 RISE UP trial of PYRUKYND in sickle cell disease along with the no go — meaning the go/no go call on moving to Phase 3. Before this year ends, our expectation is to have enrolled over half the patients across the Phase 3 ACTIVATE-kids and ACTIVATE-kidsT trials of PYRUKYND in pediatric PK deficiency. We also expect to finish bringing patients into the Phase 2a trial of AG-946, our novel PK activator, in lower risk MDS, and to submit the IND for our PAH stabilizer aimed at treating PKU. All through the year, our goal is to keep bolstering commercial capabilities via the launch we have going in PK deficiency, and to keep assessing BD opportunities that could broaden the pipeline. Turning to 2024 through 2026, we look for a span packed with catalysts, with the possibility of two further PYRUKYND indications arriving in that window. To be specific, during 2024, we expect readouts from the Phase 3 trials of PYRUKYND in thalassemia, and also the readout from the Phase 2a trial of AG-946 in lower risk MDS. During 2025, we expect possible approval of PYRUKYND in thalassemia, and also Phase 3 readouts for PYRUKYND in sickle cell disease and pediatric PK deficiency. And during 2026, we expect possible approvals for PYRUKYND in sickle cell disease and in pediatric PK deficiency. Given this set of possible near-term catalysts, I anticipate a productive year as we pursue our 2026 vision for Agios: a proven hematology franchise with approvals covering three hemolytic anemias, a broader portfolio driven by business development, and progress on our internal pipeline that matches our core expertise in rare disease along with cash flow positivity; with that, I'll hand the call to Sarah now.
Sarah Gheuens
executiveThank you, Brian. During 2022, the group I oversee for research and development achieved meaningful strides in moving forward our PK activator initiatives, spanning several disease areas tied together by a common fundamental pathophysiology involving metabolic stress in red blood cells. As the biggest collections of data ever produced for any PK activator, the steady and persuasive results gathered so far with PYRUKYND in PK deficiency, thalassemia, and sickle cell disease underscore how PK activation could fix red blood cell metabolism and reshape patient function, quality of life, and long-term outcomes across each of these conditions. Our latest clinical portfolio data updates were shared at ASH in December, where Agios alongside our outside collaborators were delighted to showcase 22 abstracts altogether; among these were long-term findings from the Phase 2 trial of PYRUKYND in thalassemia, showing durable gains in hemoglobin and hemolysis along with stabilized or better erythropoiesis and iron homeostasis across 72 weeks among patients with alpha or beta non-transfusion dependent thalassemia; for PK deficiency, we shared refreshed long-term extension results showing that adults on PYRUKYND experienced lasting gains in hemoglobin; iron overload, transfusion burden, and patient reported outcomes no matter their transfusion status. We also shared new findings from the Phase 1 trial of our innovative PK activator AG-946 in healthy volunteers, revealing a favorable safety profile at pharmacologically active doses and a PK profile that supports once a day dosing. When viewed together, the clinical results gathered so far indicate that the differentiated mechanism of action of PYRUKYND is fixing red blood cell metabolism and producing steady gains in hemoglobin, hemolysis and erythropoiesis; against that backdrop, allow me now to give a quick update on the PYRUKYND development program, starting with thalassemia. As a reminder, the Phase 3 program for PYRUKYND in thalassemia consists of two randomized placebo-controlled trials, and each one is enrolling patients with both alpha and beta thalassemia. ENERGIZE is enrolling patients who are not regularly transfused with a primary endpoint of hemoglobin response, while ENERGIZE-T is enrolling patients who are regularly transfused with a primary endpoint of transfusion reduction response. Over half of the patients in each of these studies have been enrolled so far, and our goal is to finish enrollment for both studies in the middle of this year. Given the data produced in this program so far, we hold a strong belief in the potential for PYRUKYND to become the first therapy to improve hemolytic anemia and ineffective erythropoiesis in all subtypes of thalassemia and to become a foundational therapy in treating this devastating disease. We look forward to the readouts from these Phase 3 studies next year. I will now shift to sickle cell disease, where our goal is to deliver a novel oral therapy that both improves anemia and reduces vaso-occlusive crisis or VOCs. Toward that end, we are moving ahead with the operationally seamless Phase 2/3 RISE UP study of PYRUKYND in adults with sickle cell disease, and I am pleased to announce that the Phase 2 portion of this study is now fully enrolled. For the Phase 2 part of this trial, the main goals we're measuring are hemoglobin response along with safety. We anticipate sharing those Phase 2 results, plus our decision on whether to move forward into Phase 3, around the midpoint of this year. That call will rest on the go/no go criteria spelled out in the protocol for the Phase 2 portion of RISE UP, together with whatever extra information comes from the Phase 2 secondary endpoints and longer-term findings from the extension studies still running under investigator sponsorship at the NIH and the University of Utrecht. So far, those investigator sponsored trials have produced strong evidence indicating that among adults who have sickle cell disease, PYRUKYND cuts down on red blood cell sickling and, much like what we've seen in PK deficiency and thalassemia, also brings about steady gains in hemoglobin, hemolysis and erythropoiesis. Last, we keep moving forward with the Phase 3 ACTIVATE-kids and ACTIVATE-kidsT trials of PYRUKYND for pediatric PK deficiency, since our goal is to bring the first approved therapy to children who live with this condition. Our target is to have at least 50% of patients enrolled in each trial before this year ends; alongside the PYRUKYND development effort, we're also continuing work on AG-946, a novel PK activator that gives us a chance to make our PK activator franchise even stronger and follow several therapeutic routes, among them lower risk MDS. As we showed at ASH, pharmacokinetic results from the healthy volunteer arms of the Phase 1 single and multiple ascending dose trial backed a once daily dosing schedule, while pharmacodynamic results pointed to sustained activation of the glycolytic pathway, with ATP rising and 2,3-DPG falling, both in a dose-dependent manner. Combined with a favorable safety profile, we're eager to move ahead with the ongoing Phase 2 trial of AG-946 in lower risk MDS and anticipate finishing enrollment in that study's Phase 2a portion before this year is over. As Brian noted, our aim is to grow the pipeline past PK activations by way of both disciplined business development and pushing forward our earlier-stage pipeline. Among our earlier-stage efforts, we're continuing to advance our lead research program, which targets phenylketonuria, or PKU. PKU is an uncommon genetic disorder with few treatment choices, affecting roughly 35,000 to 40,000 patients overall across the U.S. and EU5, and it results from a deficiency of the phenylalanine hydroxylase, or PAH, enzyme. When PAH activity is lacking, phenylalanine builds up along with downstream sequelae, so patients with PKU are frequently told to follow a severely restricted diet to keep phenylalanine intake low, which can lower patient quality of life even further. To tackle the root cause of PKU head-on, we're creating an oral PAH stabilizer intended to bring phenylalanine levels down, and we're aiming for an IND filing for this program before this year ends. All in all, I'm quite happy about how much ground the team covered while carrying out work throughout our portfolio during 2022, and I'm eager to see our 5 pivotal trials that are still underway keep maturing as 2023 goes on. So with that said, I'll hand things over now to Tsveta.
Tsveta Milanova
executiveI appreciate that, Sarah. After coming aboard Agios just last month, what has struck me is the discipline shown by the commercial organization, the strong evidence coming out of all our clinical programs, and how much promise the portfolio holds for changing how several rare blood disorders are treated. Being able to become part of a business so evidently positioned for growth both near term and long term is a genuine privilege. Over the past two decades, I have overseen worldwide rare disease product introductions at major biopharma firms. Every one of those introductions brought its own set of obstacles, yet my central objective never shifted: to shorten how long patients spend on their journey and to enhance health outcomes for patients as effectively as possible. Reaching that objective, especially when a disease is ultra-rare, demands putting in place and executing a thorough commercial plan that touches every stage of the patient journey, all the way from creating disease awareness through to securing reimbursement. More precisely, such a plan has to rest on three central pillars: boosting knowledge of the disease and providing education about the treatment choices that exist; speeding up access by cutting down the interval from diagnosis to the start of treatment; and backing adherence while sustaining reimbursement across the long term. With this approach as my foundation, my foremost priority is to push for operational excellence in the ongoing PK deficiency launch and to develop the capabilities required to capture the full commercial opportunity for PYRUKYND in the launches we expect ahead in thalassemia and sickle cell disease. Looking back over the launch so far, what has especially encouraged me is how far the team has come on market access. Payer policies line up with the label or with clinical trial inclusion criteria, and prior authorization requirements match what we anticipated, with most patients beginning therapy 4 to 6 weeks after they finish the prescription enrollment form, or PEF. Since launch, discontinuations have stayed low on the whole, and reauthorizations have not stood in the way. This momentum underscores both the favorable effect of PYRUKYND and the strength of our market access and patient services capabilities. During the fourth quarter of 2022, which was the third complete quarter since launch, net PYRUKYND revenue reached $4.3 million. 105 patients in total have now finished a PEF, among them 21 during the fourth quarter of 2022, which is a 25% rise compared with the third quarter. Because our conversion rate is strong, that has amounted to a net of 78 patients receiving therapy, a 39% gain over Q3. The patients receiving therapy come from an expanding and varied prescriber base made up of 96 physicians, and they reflect a wide demographic and disease manifestation range that aligns with the adult PK deficiency population. Even with this momentum, we have spotted a number of areas where we can do better. As tends to happen with ultra-rare disease launches, we have seen a broad shortage of disease awareness along with a matching absence of urgency when it comes to diagnosing, monitoring and treating. That creates an obvious opening to direct more attention toward the earlier phases of the patient journey, and by doing so, lift disease awareness and diagnostic efficiency. To be specific, since the ICD-10 code used for diagnosing PK deficiency has only been around for under 2 years, we intend to ramp up our disease awareness work by enhancing our AI and machine learning tools so we can spot high potential clinicians who are likely to treat patients with PK deficiency. Also, because the prescriber base is so broad and diverse, we want to improve our ability to engage and educate treating physicians, including about the anemia ID program being available, which offers no cause genetic testing to identify a range of hemolytic anemia, including PK deficiency. I have confidence that continuing to strengthen these rare disease capabilities will assist us in maximizing the potential of the current launch. However, PK deficiency is just the start, and developing our capabilities to support diagnosis, education, access and adherence will directly translate to future potential launches in meaningfully larger patient population and will assist us in unlocking the full commercial potential of our PK activated franchise. With that, I will now hand the call over to Cecilia.
Cecilia Jones
executiveThank you, Tsveta. The financial results we announced this morning for both the fourth quarter and the full year 2022 are available in our press release, and I'll walk through the highlights. Additional specifics will appear in our 10-K, which gets filed later today. Net revenue for PYRUKYND across full-year 2022 came to $11.7 million, with $4.3 million of that generated during the fourth quarter — a $0.8 million gain over Q3. Because PYRUKYND is the very first treatment approved for this ultra-rare patient group, we are still accumulating data and insights regarding how the launch is progressing, so no guidance is being offered right now. In line with what we see with other rare disease product launches, gross to net remains within the 10% to 20% band. Cost of sales for the quarter totaled $0.4 million. Now on to expenses and the balance sheet. R&D costs reached $70.3 million in the fourth quarter and $279.9 million across full-year 2022, which is $22.9 million higher than full-year 2021. That year-over-year rise came mainly from greater spending on our five ongoing PYRUKYND pivotal studies as well as the AG-946 studies, plus a larger workforce across R&D. SG&A expenses came to $32.8 million for the fourth quarter and $121.7 million for full-year 2022, up $0.3 million versus full-year 2021. Royalty revenue for TIBSOVO across the full year — recorded under royalty income from gain on sale of oncology business on our income statement — was $9.9 million. Keep in mind that TIBSOVO royalty income stopped after Q3 2022, following the sale of our rights to 5% royalties on U.S. net sales of TIBSOVO to Sagard for a one-time payment of $131.8 million in October, of which $127.9 million was recorded under other income in Q4. Through the divestiture of our oncology business to Servier, we kept rights to a potential $200 million milestone upon approval plus 15% royalties on potential U.S. net sales of vorasidenib, a clinical stage dual inhibitor of mutant IDH1/2; we closed out the year with cash, cash equivalents and marketable securities of approximately $1.1 billion; we anticipate that our cash, cash equivalents and marketable securities, along with expected product revenue and interest income, will let us carry out our operating plan — including funding the currently planned development programs for mitapivat, AG-946 and PAH and commercializing mitapivat outside of the U.S. through one or more partnerships — to reach cash flow positivity without any need to raise additional equity. To preserve our strong cash position, we'll stay focused on proactively managing our cost base and applying a disciplined capital allocation approach, ensuring our ongoing pivotal studies are fully developed and preserving flexibility to expand our pipelines through business development. I'll now hand the call back to Brian for his closing remarks.
Brian Goff
executiveThank you, Cecilia. At Agios, 2022 brought enormous strides forward. Following PYRUKYND's clearance for use in adults who have PK deficiency, we've achieved a significant initial milestone on the path toward what we aim to accomplish by 2026, and we stayed dedicated to moving along our best-in-class portfolio of PK activators, which is aimed at the serious unmet requirements of individuals affected by uncommon blood disorders. Looking to 2023, we expect several pivotal clinical and regulatory events that should set the stage for possible Phase 3 results in thalassemia, sickle cell disease, and pediatric PK deficiency across the coming years. As ever, we'll work to manage our balance sheet prudently and keep assessing substantial chances to generate value. Last, I want to express gratitude to each of our team members for their effort and commitment to our goal of changing the lives of people dealing with rare diseases, as well as every one of our collaborators, among them doctors, caregivers, patients, and those enrolled in our clinical development programs. Having said that, we'll now begin taking questions.
Chris Raymond
analystHey, thank you folks for fielding the question. I suppose just a handful of things. To start, regarding the Phase 2 sickle cell — the Phase 2 portion of your study reporting results at mid-year. I realize you all have mentioned that the primary endpoint is hemoglobin response, but is there a possibility to demonstrate a VOC signal, at minimum, within this portion of the study? Could you clarify that? And then I have something else to ask?
Sarah Gheuens
executiveOf course. So, hello, I'm Sarah. So regarding the Phase 2 portion of the study, we do indeed have a primary endpoint of hemoglobin response and safety as the initial path. But then among our secondary endpoints, we are in fact capturing the rate of VOCs too. Having said that, it is in fact a 12-week period for the randomized control trial. So the data that comes from that will be limited by how long patients have been exposed to the drug. As we always have, we've consistently stated this too, that we will be examining the totality of the data generated in the study, particularly in the RISE UP trial, and we will additionally be examining our investigator sponsored trials where patients have been exposed for a longer duration.
Chris Raymond
analystAll right, that sounds good. Thank you. Moving on to PYRUKYND in Europe — from what I understand, you already hold marketing authorization both in Europe and the UK, and Brian, you've mentioned that you don't want to establish a substantial infrastructure over there, I believe until a broader indication comes through. So perhaps you could share any news on the approach to launching in that region, particularly now that the marketing authorization is secured.
Brian Goff
executiveYes. Good morning, Chris. That's an excellent question. So, as you pointed out, we have said before that when it comes to commercializing outside the U.S., we're interested in one or more partners. PKD, as you're aware, is an ultra-rare indication, and attempting to commercialize for PKD alone would be a considerable undertaking. What we're aiming toward, then, is that as things move forward — as Sarah just referenced regarding the sickle cell data, and especially thalassemia, where we've said we anticipate having full enrollment by mid-year — that positions us to systematically pursue partners who we feel will do an excellent job of representing the global footprint we foresee for those upcoming launches. PKD, naturally, as I said, is extremely rare, while thalassemia represents a considerably bigger opportunity, and much like sickle cell disease, it carries a distinct worldwide footprint. Those, then, are the elements that will shape our partnering approach.
Marc Frahm
analystHello, and thank you for answering my questions. Perhaps I'll just piggyback on what Chris asked. I'm simply considering the Phase 2 data that's coming our way. When it comes to deciding whether to proceed or not with Phase 3, do you just need to observe something somewhat more solid, yet essentially comparable information to what you've already witnessed regarding hemoglobin and similar measures? Or are there genuinely novel endpoints that must emerge from these results before you'd feel inclined to move ahead with Phase 3?
Sarah Gheuens
executiveThe endpoints, in fact, are fairly comparable to those in our other studies; nonetheless, this marks the initial placebo-controlled datasets within our Phase 2. That's why we're genuinely thrilled about it. And indeed, we're looking forward to mid-year with a great deal of anticipation.
Brian Goff
executiveAlso, Marc, I'd like to chime in on that. What we've repeatedly discussed as being such an attractive feature of PYRUKYND is how consistent the results have looked in hemolytic anemias and PKD, and continuing all the way through launch, plus thalassemia — that one's already finished Phase 2, and Phase 3 is now in progress. And, as you're aware, RISE UP is where we're awaiting the Phase 2 readout. We don't anticipate surprises, so to speak, but should compelling results emerge from the Phase 2 RISE UP trial, it would serve as confirmation. The endpoints, naturally, have been established, and after that we'll review the full body of data, just as Sarah mentioned a moment ago.
Marc Frahm
analystAll right, and thank you. So perhaps regarding the PKD launch, the fourth quarter is essentially the initial complete quarter with a number of patients going through reauthorizations and similar processes, and that pattern is persisting in the current quarter. What exactly are you observing when it comes to the reauthorization criteria being used? And what proportion of patients would you estimate — ought we to anticipate they will stay on treatment over the long term?
Tsveta Milanova
executiveMany thanks for asking that. This is Tsveta speaking. As we mentioned, at the close of the fourth quarter of 2022, we had 78 net patients receiving therapy; and that net patient figure encompasses every patient who has begun treatment along with every patient who has stopped; we have not arranged to report any particular figures regarding discontinuations; however, as we pointed out, for those patients arriving at that six months assessment, the reauthorization rate has not proven to be an obstacle whatsoever up to now. Discontinuations are still at a lower level — low on the whole for the products, and to me, that genuinely strengthens the favorable response we receive from patients, physicians and payers regarding the profile of PYRUKYND in the U.S.
Mary Kate
analystHello, and this is Mary Kate sitting in for Greg. We appreciate you taking our questions. I suppose now that a year has passed since PYRUKYND PKD received approval, you've noted roughly 96 distinct physicians writing prescriptions. How might usage and updates shift as doctors gain more familiarity and experience with PYRUKYND?
Tsveta Milanova
executiveWe're genuinely quite happy with how far we've come on the prescribing breadth front. As you just said, 96 distinct physicians have produced 105 prescription enrollment forms. This is an ultra-rare disease, so broadening prescribing reach will remain our central priority for data and going forward; we must remember that this takes time, since every one of those unique prescribers essentially has to travel their own path through disease awareness, diagnosis and prescription too; that's actually among the key reasons we'll place heavier emphasis on this earliest portion of the patient journey — truly cutting down the interval between diagnosis and treatment and directing more resources toward data and analytics to support diagnostic efficiency and, quite importantly, to sharpen our targeting work with clinicians too.
Brian Goff
executiveCorrect. I would simply add that when you launch a product for an ultra-rare condition, the kinetics — as Tsveta pointed out — truly come down to how broadly physicians prescribe it. We frequently characterize this as being an inch deep and a mile wide, since with PKD it would be rare for a doctor to have more than 1 or 2, or possibly 3, patients at most. So the work Tsveta mentions regarding education first and foremost, which matters enormously. And second, as she hinted at earlier, the machine learning tools we are developing through claims database analysis matter enormously too. For rare disease launches, this is a state-of-the-art capability that we intend to master, because the better we can be at efficiently directing our call plan targeting toward high potential prescribers who probably have a PKD patient, the more successful our breadth expansion will be — and that genuinely stands as one of the main areas we are concentrating on.
Mary Kate
analystExcellent, thank you. Then, may I ask one additional question for those who are on treatment or who already prescribe PYRUKYND — what sort of feedback are you hearing from patients and physicians who either take or prescribe this drug? Thanks.
Tsveta Milanova
executiveThe feedback we're receiving makes us quite happy, and it comes from every direction — patients, physicians, and payers too. I'd say the way our market access work has succeeded really shows how positively payers have responded, both regarding patients starting therapy and the strong results we're seeing on the reauthorization rate. Our patient services team passes along plenty of encouraging anecdotal comments, which is wonderful to learn about. In fact, during my very first month in this role, I got to go out into the field and meet some customers, so I heard a portion of that feedback firsthand. It truly underscores the favorable impression — not just of how the product is perceived, but of the experience already gained this early in the launch with how well PYRUKYND works for those patients; so that makes us enthusiastic. Like we've mentioned, it will require a bit of time, yet I think we're establishing several of the correct components to keep moving toward the appropriate scope of prescribing.
Brian Goff
executiveThis is regarding PKD, and honestly, that's quite promising. Sarah, would you like to share your thoughts about the experience with the clinical trial?
Sarah Gheuens
executiveAbsolutely. In a sense, it's quite comparable how the long-term data collection continues in the clinical trial for PKD patients who by now have received PYRUKYND for an extended period, and what we're observing is that our data keeps getting stronger as it matures, partly since the hemoglobin effect holds steady and the influence on hemolysis holds steady too. Crucially, we're seeing patient reported outcomes that likewise hold steady and genuinely hit that threshold of clinical significance when it comes to feeling better and functioning better. And beyond that, something we're really enthusiastic about is our iron overload data too, where we're beginning to observe an ever-growing effect on iron overload as well. So I'd say we're quite thrilled by what PYRUKYND has already provided and keeps providing for PKD patients.
Tessa Romero
analystMorning, Brian, and everyone else. Thanks for letting us ask. I've only got one, about the sickle cell disease program, if that's alright. When you think about the Phase 2 RISE UP results and how they feed into your go/no go call — is there a specific quantitative hemoglobin response rate that, in your view, counts as differentiated? And I realize that in earlier conversations, vaso-occlusive crises came up as another thing worth watching. So could you give us a clearer sense of what would count as an encouraging trend on VOCs too?
Tsveta Milanova
executiveOur primary endpoint is hemoglobin response, correct? The threshold we've established is 1 gram per deciliter for something to qualify as a hemoglobin response, measured between particular time points within the trial. Our protocol has pre-specified what counts as statistically significant for the primary endpoints, and then the way we proceed into testing the secondary endpoint — so this is a fairly classic Phase 2 design. For Phase 2, naturally, what we want from the secondary endpoint is trends. With VOCs, we're now collecting them over time. That data will accrue, but we aren't expecting something enormously impactful or meaningful there, since Phase 3 is ultimately what will deliver that. And Phase 3 is designed to genuinely deliver against our target product profile, where our hope is to treat sickle cell disease in its totality by affecting both hemolytic anemia and sickle cell pain crisis, plus there's this additional opportunity to then further address patient reported outcome — so really offering a drug that matters across the whole of sickle cell.
Gregory Renza
analystExcellent. Thank you. Good morning, Brian and everyone. Nicely done on the advances, and I appreciate you fielding my question. Brian, perhaps shifting our attention to 2026 and those comments regarding positive cash flow. I simply wanted to hand you a chance to maybe share some detail about a few of those presumptions and the way you're viewing the inputs needed to reach that point. Naturally bearing in mind the launch, the numerous programs under development, and then, obviously, what you said about evaluating external assets and the pipeline. Many thanks.
Brian Goff
executiveCertainly. Thank you. Good morning, Greg. Cecilia is going to begin.
Cecilia Jones
executiveAbsolutely. Greg, I appreciate that question. As we said, our cash, cash equivalents, and marketable securities — together with the product revenue and interest income we expect — will allow us to carry out the plan we have now. That plan covers every pivotal trial Sarah laid out for mitapivat and PKD pediatric, thalassemia, and sickle cell, as well as AG-946 and the earlier program in PAH. And, as Brian mentioned before, part of that plan involves commercializing mitapivat outside the U.S.
Gregory Renza
analystUnderstood. And if you could just give some additional perspective — even regarding the top line, I realize guidance isn't being requested — but when you consider PYRUKYND as a foundational treatment and what it might do across each of these indications, how do you envision the pace at which that possibility stacks up as you progress through development and possible approvals during the mid-20s? Many thanks.
Brian Goff
executiveSure, Greg. When it comes to PKD, we definitely hold an ambition of making the most of the PKD launch opportunity. And naturally, the larger objective for us is to bolster our commercial strengths for these considerably bigger sequential launches that may arrive, specifically thalassemia and sickle cell disease. Regarding PKD, it is ultra-rare both in name and in nature. Consequently, it's going to require a while for us to sharpen the prevalence figures along with peak sales projections as our knowledge grows. Beyond that, I'd say peak sales hinges on numerous elements, such as how long it takes to reach peak sales, the timelines for approvals, distribution and partnerships as we discussed regarding outside the U.S., and from our current position, this conversation captures only the third full quarter of launch, and thus far it's evident to us that the PKD launch is going to be slow and steady. I believe that comes through in the figures we keep reporting. I'll add, and I'm simply going to use this moment to restate that I'm extremely happy Tsveta Milanova has come aboard as CCO, since Tsveta brings profound knowledge and background in rare disease launches. And I think that timing couldn't be better for us as we aim to sustain the momentum of the PKD launch and, even more crucially, prepare for these vigorous launches that could be on the way.
Mark Breidenbach
analystHi there, good morning. I've gotten answers to the majority of what I wanted to ask, though let me go a bit deeper into the earlier-stage pipeline. Could you perhaps walk us through what sets the PAH stabilizer for PKU apart from sapropterin and other medicines that already have approval or are far along in development for PKU? Thanks.
Sarah Gheuens
executiveOf course. Sarah here. Our program truly does work through a mechanism that differs from the rest of what's either in development right now, or has received approval and been sold for some time. So yes, it is a PAH stabilizer, and that makes it distinct. The opening we perceive for this product comes from the fact that the 2 options on the market today each carry their own drawbacks when it comes to treating PKU, whether that's a heavy pill burden or delivery by subcutaneous injection. A great deal comes with that, and it's why we're aiming to create an oral treatment capable of addressing most PKU cases. Naturally, we're hoping to deliver something that stands out in a meaningful way — offering every benefit as measured through phenylalanine reductions, while also being simpler to use and simpler to tolerate; further specifics about our CDPs will be shared as the program moves forward.
Brian Goff
executiveAlso, Mark, let me mention this: the addressable market here is substantial. What we're discussing is a further step-change in prevalence compared with our current situation with PKD. That would involve 35,000 to 40,000 patients in the U.S. and EU5 combined; plus, another thing about this program is that it stems from our Agios know-how in cellular metabolism. So at present it's quite early; we've mentioned a possible route to an IND by the close of this year. Still, we're eager to see this as a possible further diversification of our pipeline.
Danielle Brill
analystHello everyone, good morning. I really appreciate you taking the questions. I've got a few. To begin with, regarding 946, I just want something clarified — could you walk us through what's planned for the Phase 1 sickle cell cohort currently being enrolled? How is that progressing, and what are your intentions when it comes to data? Then, about PYRUKYND, I'd like some clarity: does that figure of 78 patients on drug account for discontinuation, or is it the overall count of patients who have gotten PYRUKYND? And I have one more question after that.
Brian Goff
executiveAbsolutely; Sarah, why don't you take the first one.
Sarah Gheuens
executiveAbsolutely, and I appreciate the questions. Regarding 946 in sickle cell disease — we've finished and made public every result from our Phase 1 study in healthy volunteers. Inside that study, there is in fact a cohort still running for sickle cell disease, and it follows a multiple ascending dose design within that Phase 1 for sickle cell disease, where the goal specifically is to produce data in the setting of hemolytic anemia. So this is a trial of brief duration. We haven't said when those results will come out. That trial is still underway and is currently on schedule. We're extremely enthusiastic. So with 946 — and I realize you didn't ask about this, but I simply want to mention it, since we're very excited about where we stand with our MDS program, which right now sits in the Phase 2a portion of that particular trial.
Brian Goff
executiveMoving on to Tsveta — on the patient side, my sense is that one will be straightforward, though I appreciate that Danielle raised it. It's helpful to clear that up.
Tsveta Milanova
executiveJust to make that clear. Yeah, so the 78 patients receiving therapy when Q4 closed is truly a net figure for patients. That means it counts those who began treatment, minus those who stopped, and every one of those 78 patients was in fact actively getting PYRUKYND when the quarter ended.
Brian Goff
executiveAlso, one more point from me: the rates of discontinuation for what we've launched so far have come in at a low level, and that's really encouraging, since it tells us PYRUKYND is doing quite well when it comes to both patients and providers. And when we shift our view past PKD, that stands as a highly meaningful data point for us as we consider the larger launches still ahead.
Danielle Brill
analystAll right, thank you. That is quite useful. My next question, then, concerns the enrollment form. I would like to know how many of those end up becoming patients who receive the drug.
Tsveta Milanova
executiveRegarding the PEF, we feel quite good about where we stand on market access and patient services, since most PEFs do move forward into treatment initiation. Some lag exists between finishing a PEF and starting treatment. Currently that runs roughly 4 to 6 weeks, and we don't anticipate a meaningful reduction in that window. The main reason is that many payer policies and prior authorization criteria call for genetic testing. When a patient hasn't had a genetic test done, or the results aren't available, they must complete that process, and the sheer timing of genetic testing is what dictates the 4 to 6 weeks.
Brian Goff
executiveRight. In an ultra-rare disease launch, the real difficulty actually lies in creating PEF, that demand, since the condition is so uncommon and a great deal of hard work is needed when it comes to education pieces. My view is that converting PEF into patients actually on therapy is going to take a while, though in itself that isn't the genuine obstacle of the launch.
Analyst
analystMorning. I'm < >, filling in for Salveen. To start, regarding that sickle cell update expected around mid-2023, what's the main thing we ought to watch? Also, from where you stand, how would you define success for the Phase 2 part? And on the flip side, what would push you toward a no go call? Thanks.
Sarah Gheuens
executiveFor Phase 2, we've got pre-specified thresholds for our primary endpoints, and those primary endpoints are hemoglobin response plus safety. Among the secondary endpoints, we have hemolytic markers, patient supported outcome, and VOC; first off, we aim to clear the bars on our primary endpoint; we — and there are two doses being tested against placebo; so we'll examine both doses to determine which is the better dose to advance into Phase 3; all of that is pre-specified within the protocol. Beyond that, when it comes to an overall go/no go call for the program, additional data will factor in, such as our investigator sponsored trials. And naturally, as with every program we have, whenever we move toward the next stage of development, we confirm that we genuinely believe we will achieve our target product profile. That's the discipline we apply here, and to all of our programs. And we're quite eager for mid-year to arrive so we can actually discuss data.
Analyst
analystThanks. I suppose, just as a follow-up on that point, what would the ideal target profile look like for PYRUKYND and sickle cell?
Sarah Gheuens
executiveOur ideal target product profile is genuinely a kind of product able to provide benefit for sickle cell disease pathology — that is, we have programs built to address hemolytic anemia and achieve a decrease in sickle cell pain crisis; beyond that, we also hope to show a benefit on CROs.
Analyst
analystIf you don't — sorry, I'm — just one more thing. I suppose that in the event that you see no betterment when it comes to the VOC rates, would that play into your choice to not proceed with the trial?
Sarah Gheuens
executiveSo the data we have from our Phase 2 regarding VOCs is going to be quite limited, purely due to how long the trial runs; there's a 12-week randomized controlled trial portion; so showing a huge benefit on VOC is not what the trial was built to do. So we keep gathering data on VOCs through our open-label extension in the Phase 2, and then naturally, we have far longer exposure by way of our investigator sponsored trials.
Brian Goff
executiveOkay, thank you so much, everyone, for joining us on this call today, and naturally, for the ongoing attention you give to Agios. As was shared with you earlier today, we are building considerable momentum toward the vision we hold for the long term, and we feel certain about our ability to create substantial value for patients as well as for shareholders. So, thank you once more, and we can't wait to talk with each of you again very shortly.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.